HNRNPC, or heterogeneous nuclear ribonucleoprotein C, belongs to a large family of RNA-binding proteins that patrol the nucleus of every human cell. Its core job is deceptively simple: it grabs onto newly made RNA molecules and helps decide their fate. But as the review by Zezhao Ji, Yanbin Peng, Abduxukur Ablimit, Zhiwei Liang, and Lixin Wang makes clear, that simple-sounding task cascades into nearly every layer of gene regulation. Through its RNA recognition motifs—the protein domains that physically clasp onto RNA—HNRNPC influences how pre-messenger RNA transcripts are spliced into their mature forms, how stable those transcripts are once assembled, how efficiently they are translated into proteins, and how they interact with the sprawling world of non-coding RNAs that fine-tune cellular behavior.

Perhaps the most consequential of HNRNPC’s functions involves N6-methyladenosine, or m⁶A, the most abundant chemical tag on messenger RNA in mammalian cells. This epitranscriptomic mark, added and removed by dedicated enzyme systems, acts like a molecular zip code that tells reader proteins how to handle a given transcript. HNRNPC functions as one of those readers, and it does so in an unusual way. Rather than recognizing the m⁶A mark directly, it binds methylated RNA regions indirectly, because the methyl group causes local structural changes in the RNA that expose sites HNRNPC prefers to occupy. The consequence is dramatic: by latching onto these regions, HNRNPC can open up or obscure binding sites for other splicing regulators, effectively rewriting the splicing patterns of hundreds of genes at once. The review emphasizes that HNRNPC can also act entirely independently of m⁶A, giving the protein dual modes of action that complicate but also enrich its biological portfolio.

The downstream consequences of this dual-mode regulation are anything but academic. In tumor cells, HNRNPC behaves as a volume knob for oncogenic programs. The review documents how aberrant HNRNPC expression promotes epithelial-mesenchymal transition, the cellular shape-shifting process through which cancer cells gain the mobility needed to invade surrounding tissue and seed metastases. It also modulates programmed death-ligand 1, or PD-L1, the molecular shield that tumors raise against immune attack, thereby influencing how cancer patients respond to immunotherapy. Levels of HNRNPC additionally correlate with tumor mutational burden, an established predictor of immunotherapy outcomes, suggesting that this RNA-binding protein sits at a junction between RNA metabolism and the immune landscape of cancer. Depending on context and target genes, HNRNPC can act either as an oncogene pushing disease forward or as a protective factor restraining it—a duality the authors stress must be resolved before the protein can be safely exploited in the clinic.

That dual nature reflects a broader theme of the review: HNRNPC is not a simple on-off switch. The protein is subject to an array of post-translational modifications that alter its behavior, and it operates within multiprotein complexes where other heterogeneous nuclear ribonucleoproteins and splicing factors modulate its reach. It also intersects with processes such as alternative polyadenylation, which determines where the tail of a messenger RNA is trimmed and extended, affecting transcript stability and translation efficiency. Through its interactions with long non-coding RNAs, circular RNAs, and microRNAs, HNRNPC participates in competing endogenous RNA networks in which different RNA species sequester one another’s regulators, producing ripple effects throughout the cell’s regulatory circuitry.

What elevates the review from molecular biology into clinical territory is its synthesis of HNRNPC’s role in diseases far beyond cancer. In neuropsychiatric conditions, disrupted HNRNPC function has been linked to aberrant RNA processing in neurons, where precisely calibrated splicing is critical for synaptic function and neural development. In reproductive and metabolic diseases, altered expression of the protein appears to disturb gene programs governing hormone responsiveness and energy homeostasis. The review also details HNRNPC’s entanglement with infectious and inflammatory disease: the protein engages with hepatitis B virus and hantavirus during infection, and it influences inflammatory signaling pathways, including effects on tumor necrosis factor alpha induced protein 6, an effector molecule in inflammatory cascades. These connections suggest that a single RNA-binding protein helps mediate how human cells respond to pathogens and inflammatory stress, opening potential avenues for antiviral and anti-inflammatory intervention.

The translational implications are captured in three distinct roles the authors assign to HNRNPC. As a diagnostic biomarker, abnormal HNRNPC expression profiles in patient tissues or biofluids could help identify disease earlier or classify it more precisely than current methods allow. As a prognostic predictor, the protein’s expression levels correlate with disease progression and poor clinical outcomes across multiple cancer types, meaning a simple measurement could inform how aggressively a tumor is likely to behave and which patients need closer surveillance. As a therapeutic target, HNRNPC is now within reach of emerging drug modalities. Antisense oligonucleotides, short synthetic strands that bind RNA with programmable specificity, could be designed to disrupt the HNRNPC-dependent splicing events that drive disease. Because HNRNPC’s pathogenic effects often run through m⁶A-dependent mechanisms, the growing pharmacopoeia of methyltransferase and demethylase inhibitors offers another route to indirect modulation.

The timing of this synthesis is significant. Epitranscriptomics, the study of chemical modifications to RNA, has moved from a niche curiosity to one of the fastest-growing fields in molecular biology over the past decade. The discovery that m⁶A marks recruit reader proteins such as HNRNPC to reshape RNA processing won foundational recognition and has since spawned a global effort to map, perturb, and therapeutically exploit the RNA modification landscape. HNRNPC sits squarely at the center of that effort, not only as an m⁶A reader but as a demonstrated example of how a modification can exert biological effects indirectly, through structural changes in the RNA rather than direct recognition. Understanding such indirect mechanisms is essential for the rational design of drugs targeting the m⁶A system, because inhibiting the writer enzymes may produce effects that propagate through multiple distinct reader proteins with different, sometimes opposing, consequences.

The authors are candid about the unresolved questions that temper enthusiasm. Context dependency remains the field’s central puzzle: the same protein can be oncogenic in one tissue and protective in another, and the determinants of that switch are only partially mapped. The precise structural basis of HNRNPC’s indirect recognition of methylated RNA regions has been worked out in model systems but not fully characterized across the diversity of human transcripts. The interplay between HNRNPC’s post-translational modifications and its RNA-binding preferences is largely unexplored. And translating laboratory findings into clinical biomarkers will require standardized assays, large patient cohorts, and prospective validation—none of which yet exist at scale. The review frames these gaps not as setbacks but as a research roadmap, identifying where focused investment is most likely to yield diagnostic and therapeutic dividends.

Funded by the Shanghai Municipal Key Clinical Discipline of Traditional Chinese Medicine Interdisciplinary Innovation Oncology and Shanghai Tongji Hospital, the work reflects a growing recognition in oncology research that the post-transcriptional layer of gene regulation is fertile ground for clinical innovation. The authors, drawn from Tongji Hospital, Shanghai Pulmonary Hospital, and Xinjiang Medical University, span pathology, integrated medicine, and basic medical science—an interdisciplinary blend suited to a subject that refuses to stay within any single organ system or disease category. Corresponding author Lixin Wang and colleagues argue that as epitranscriptomics matures, HNRNPC is positioned to become a core molecular target for the precision diagnosis and treatment of multiple diseases, a claim the review supports with a systematic accounting of the protein’s expression profiles, pathogenic mechanisms, and clinical associations across organ systems. For clinicians and drug developers, the message is that the era of targeting RNA-binding proteins is arriving, and HNRNPC is among the most compelling candidates to lead it. For patients, it means that a protein once known only to RNA biologists may soon appear in diagnostic panels and clinical trials that translate RNA biology into measurable survival gains.

Non-affective psychosis, encompassing conditions such as schizophrenia, represents a complex constellation of symptoms that includes hallucinations, delusions, and cognitive dysfunction, impacting millions globally. Traditional neuroimaging methods have long provided a window into the brain’s architecture in these disorders, yet a precise characterization of aberrant functional networks has remained elusive. FUNCATA emerges as a powerful tool by offering a detailed comparative mapping of network areas and their topographical characteristics, thereby enabling researchers to detect subtle but critical anomalies that might underlie the disorder’s manifestation.

The study’s approach hinges on comparative analyses of functional brain areas — essentially, regions with coordinated activity patterns — and their spatial configurations relative to normative data. Employing advanced neuroimaging datasets and sophisticated statistical frameworks, the team meticulously quantified variations in the size, shape, and positioning of these functional areas across large cohorts of patients and controls. This methodological precision marks a departure from earlier studies, which primarily relied on global connectivity indices or less refined regional analyses prone to averaging out meaningful heterogeneity.

One of the pivotal revelations from this replication effort was the consistent demonstration of altered topography within the default mode network (DMN) and salience network — two networks heavily implicated in self-referential thought, cognitive control, and the processing of salient stimuli. The DMN, commonly associated with introspective mental activity, showed reductions not only in overall functional area but also exhibited atypical spatial displacement when compared to neurotypical counterparts. Concurrently, the salience network, which mediates attention and the detection of behaviorally relevant stimuli, displayed comparable disruptions, suggesting a systemic reconfiguration of neural circuits critical for cognitive and emotional regulation in psychosis.

Beyond these core networks, the study provided evidence of widespread network disruption, encompassing the frontoparietal control system and subcortical hubs. The frontoparietal network, fundamental for executive functioning and decision-making, revealed diminished functional territory coupled with altered regional interplay, potentially underpinning the cognitive deficits observed in non-affective psychosis. Meanwhile, aberrations in subcortical structures hint at complex pathophysiological mechanisms that might drive dopaminergic dysregulation and affective disturbances characteristic of these illnesses.

Methodologically, FUNCATA leverages multivariate pattern analysis and machine learning classifiers to dissect the nuanced spatial properties of functional networks at an individual level. This approach fosters greater sensitivity to intersubject variability, a crucial advancement given the heterogeneity of psychotic disorders. Moreover, by replicating findings across independent cohorts, the research fortifies the reproducibility and robustness of its conclusions, addressing a persistent challenge in psychiatric neuroscience where inconsistency often clouds interpretative confidence.

The implications of these findings extend well beyond academic curiosity. By mapping precise alterations in functional network topography, researchers pave the way for novel biomarkers that could enhance diagnostic accuracy and individualize treatment strategies. Functional network area metrics derived from FUNCATA might serve as neurobiological signatures to track disease progression or treatment response, enabling clinicians to tailor interventions more effectively and perhaps even intervene preemptively to halt or slow the trajectory of the disorder.

Furthermore, this refined understanding of neural circuitry disruptions offers fertile ground for exploring new therapeutic targets. Interventions aiming to normalize or compensate for topographical aberrations in key networks, possibly via neurostimulation techniques such as transcranial magnetic stimulation or targeted pharmacotherapy, may emerge as promising avenues. The nuanced characterization of network alterations also contributes crucial insights into the etiology of psychosis, clarifying how genetic, developmental, and environmental factors converge on specific brain systems to produce clinical phenotypes.

The replication study also underscores the importance of methodological rigor and data sharing within the neuroscience community. By deploying standardized analytic pipelines and openly sharing datasets, the authors promote transparency and facilitate collaborative efforts to unravel the complexity of brain disorders. This culture of openness accelerates scientific progress and maximizes the translational potential of neuroscience research, linking bench discoveries more seamlessly to bedside applications.

It is worth noting that the study deploys state-of-the-art neuroimaging modalities, predominantly resting-state functional magnetic resonance imaging (fMRI), which captures spontaneous brain activity patterns with exquisite temporal and spatial resolution. Coupled with robust preprocessing techniques to minimize noise and artifact influence, the dataset ensures high-fidelity data upon which the FUNCATA framework operates. These technical refinements are critical given that subtle topographical changes necessitate granular data precision to avoid confounding interpretations.

In a wider context, the successful replication highlights a paradigm shift in psychiatric neuroscience from a predominantly reductionist approach, focusing on isolated brain regions or circuits, to a comprehensive, systems-level perspective. This shift acknowledges the brain’s complexity and dynamic network interactions as central to understanding mental illness, thereby aligning psychiatric research more closely with contemporary neuroscience disciplines that emphasize connectomics and multiscale analyses.

The study’s findings also resonate with emerging theories that psychosis involves aberrant neural integration rather than mere localized dysfunction. By demonstrating spatial and area-based topographical shifts in functional networks, the data lends credence to models proposing disrupted communication flow within and between brain systems. Such models conceptualize psychosis as a network disorder, wherein dysregulated connectivity leads to the fragmentation of coherent cognitive and perceptual experiences.

Importantly, this research sets the stage for longitudinal investigations applying FUNCATA to track illness evolution, treatment effects, and potentially, remission or relapse patterns. Understanding whether and how functional network topography normalizes or further deteriorates under pharmacological or psychosocial interventions could substantially enhance personalized medicine approaches. It may also illuminate critical windows during which interventions are most efficacious.

In summary, the replication study spearheaded by Mamah and colleagues represents a milestone in functional neuroimaging of non-affective psychosis. By validating and expanding upon prior findings, and harnessing the analytic power of FUNCATA, this work delivers a sophisticated framework for dissecting the complex neural substrates of psychotic disorders. Its implications for diagnosis, treatment, and our fundamental understanding of brain network pathology are profound, promising a future where mental illnesses are no longer enigmatic but tangible and tractable brain-based disorders.

As science marches forward amid an era of technological revolution, such methodological advancements not only deepen our comprehension of psychosis but also exemplify the transformative potential of interdisciplinary collaboration. Neuroscience, psychiatry, computer science, and bioinformatics converge in this study, demonstrating how integrated approaches can unlock the intricate mysteries of the human brain and lay the groundwork for breakthroughs that may ultimately alleviate the profound burden of mental illness worldwide.

Subject of Research: Functional Brain Network Alterations in Non-Affective Psychosis

Article Title: Functional network comparative area and topography analysis (FUNCATA) in non-affective psychosis: a replication study

Article References:
Mamah, D., Chen, S., Harms, M.P. et al. Functional network comparative area and topography analysis (FUNCATA) in non-affective psychosis: a replication study. Schizophr (2026). https://doi.org/10.1038/s41537-026-00736-z

Image Credits: AI Generated

Schizophrenia, a complex neuropsychiatric disorder characterized by hallucinations, delusions, and cognitive disruptions, has long defied comprehensive biological explanations. Although genetic predisposition has been recognized as a major contributor, pinpointing exact molecular pathways remains a formidable challenge. The calmodulin protein, with its central role in intracellular calcium signaling—a process vital to neuronal communication and synaptic plasticity—has emerged as a compelling candidate for scrutiny.

The research team employed advanced genetic sequencing methods to identify subtle alterations in the calmodulin gene among a broad cohort of schizophrenia patients compared with control subjects. These variants, though minor in sequence, appeared to precipitate significant functional shifts in calmodulin’s conformation and calcium-binding affinity, suggesting altered neuronal signaling dynamics in affected individuals.

By leveraging state-of-the-art biophysical analyses, the study further characterized how these calmodulin variants influenced downstream signaling cascades. Normally, calmodulin modulates key enzymes and receptor activities, thus orchestrating synaptic responses critical to cognitive processes. The identified variants exhibited diminished efficiency in these interactions, potentially compromising calcium-mediated neurotransmission and contributing to the hallmark cognitive impairments observed in schizophrenia.

Moreover, the investigation extended to in vitro neuronal culture systems engineered to express the mutant calmodulin proteins. Astonishingly, neurons harboring these variants demonstrated aberrant synaptic plasticity—a cellular mechanism fundamental to learning and memory—highlighting a plausible link between calmodulin dysfunction and the cognitive deficits seen clinically.

Beyond molecular and cellular observations, the study’s interdisciplinary approach integrated functional MRI data from patients with identified calmodulin variants. These neuroimaging results revealed aberrant patterns of brain connectivity, particularly within cortical networks implicated in executive function and reality processing, solidifying the biological relevance of the protein’s altered activity in living brains.

Noteworthy is the study’s nuanced perspective on calmodulin’s pleiotropic roles. While indispensable for myriad cellular functions, the research underscores that small functional perturbations in calmodulin can have disproportionate neurological consequences. This sensitivity aligns neatly with the complex symptomatology and variable expressivity of schizophrenia, positing calmodulin variants as critical modulators rather than sole causative agents.

The pathophysiological insights gleaned from this work open promising avenues for targeted interventions. Pharmacological agents capable of stabilizing calmodulin’s structure or enhancing its calcium-binding properties could restore synaptic fidelity and ameliorate symptoms. These findings serve as a clarion call for drug development efforts targeting intracellular signaling proteins traditionally overlooked in psychiatric disorders.

Complementing therapeutic implications, the calmodulin variants identified offer prospective biomarkers for early diagnosis or patient stratification. Genetic screening for these variants could facilitate personalized treatment regimens, optimizing efficacy while minimizing unwanted side effects—a Holy Grail in precision psychiatry.

This study also implicitly challenges the prevailing focus on neurotransmitter imbalances alone by spotlighting intracellular signaling alterations. Such a paradigm shift broadens the conceptual framework for schizophrenia research and encourages incorporation of molecular signaling networks in future investigations.

Critically, the authors acknowledge limitations, including heterogeneity within patient cohorts and the need for longitudinal studies to elucidate these variants’ influence over disease progression and response to treatment. Nevertheless, the compelling functional data provide a robust foundation for deeper mechanistic explorations.

The multidisciplinary methodology—melding genetic analysis, biophysical characterization, neuronal modeling, and neuroimaging—exemplifies the power of integrative research approaches in unraveling complex brain disorders. This holistic strategy transcends reductionist models, capturing the multifaceted nature of psychiatric illnesses.

Importantly, the study invites broader reflection on calcium signaling pathways’ roles in other neuropsychiatric and neurodegenerative diseases. Given calmodulin’s ubiquity, subtle disruptions might contribute to a spectrum of brain dysfunctions previously underappreciated.

As this research gains traction, it is expected to galvanize scientific and clinical communities alike, fostering collaborations aimed at translating molecular insights into tangible patient benefits. Such momentum could herald a new era where schizophrenia’s enigmatic molecular roots are finally decoded and effectively targeted.

In summary, the identification and functional characterization of calmodulin variants in schizophrenia represent a significant leap forward. This landmark study not only elucidates a previously concealed layer of the disorder’s biology but also sparks hope for innovative diagnostic and therapeutic pathways, potentially transforming the lives of millions affected worldwide.

Subject of Research: Functional consequences of calmodulin variants in schizophrenia.

Article Title: Functional consequences of calmodulin variants identified among schizophrenia patients and controls.

Article References:
Jensen, H.H., Brohus, M., Hussey, J.W. et al. Functional consequences of calmodulin variants identified among schizophrenia patients and controls. Transl Psychiatry (2025). https://doi.org/10.1038/s41398-025-03735-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-025-03735-3